Table 2 Association testing of PARP-1 polymorphisms with risk of NHL
NPs | Genotype | Controls no.(%) | Cases no.(%) | OR (95% CI) |
|---|---|---|---|---|
Asp81Asp | GG | 227 (31.5) | 185 (32.5) | 1 |
| Â | GA | 349 (48.4) | 279 (49.0) | 0.99 (0.77-1.27) |
| Â | AA | 145 (20.1) | 105 (18.5) | 0.90 (0.65-1.24) |
| Â | GA+AA | 494 (68.5) | 384 (67.5) | 0.96 (0.76-1.21) |
Ala284Ala | CC | 424 (58.8) | 357 (62.4) | 1 |
| Â | CT | 264 (36.6) | 189 (33.0) | 0.85 (0.67-1.07) |
| Â | TT | 33 (4.6) | 26 (4.5) | 0.94 (0.55-1.60) |
| Â | CT+TT | 297 (41.2) | 215 (37.6) | 0.86 (0.69-1.08) |
Lys352Lys | GG | 222 (30.8) | 184 (32.1) | 1 |
| Â | GA | 353 (49.0) | 285 (49.7) | 0.98 (0.76-1.26) |
| Â | AA | 145 (20.1) | 104 (18.2) | 0.87 (0.64-1.20) |
| Â | GA+AA | 498 (69.2) | 389 (67.9) | 0.95 (0.75-1.20) |
IVS13+118 A>G | AA | 426 (59.2) | 361 (63.0) | 1 |
| Â | AG | 261 (36.3) | 188 (32.8) | 0.85 (0.67-1.07) |
| Â | GG | 33 (4.6) | 24 (4.2) | 0.86 (0.50-1.48) |
| Â | AG+GG | 294 (40.8) | 212 (37.0) | 0.85 (0.68-1.06) |
Val762Ala | TT | 221 (30.7) | 189 (33.0) | 1 |
| Â | TC | 354 (49.1) | 279 (48.7) | 0.93 (0.72-1.19) |
| Â | CC | 146 (20.2) | 105 (18.3) | 0.85 (0.62-1.17) |
| Â | TC+CC | 500 (69.3) | 384 (67.0) | 0.90 (0.71-1.14) |